Bone morphogenetic protein 6-a possible new player in pathophysiology of heart failure

Clin Exp Pharmacol Physiol. 2016 Dec;43(12):1247-1250. doi: 10.1111/1440-1681.12665.


Derangement of bone morphogenetic protein (BMP) signalling was observed in cardiovascular disorders. The present study assesses the diagnostic and prognostic value of BMP6 plasma concentration in chronic heart failure (CHF). 130 CHF patients and 32 controls participated in the study. BMP6 plasma level was measured at baseline. During 12-month follow-up death and hospitalisation with CHF exacerbation were recorded. BMP6 was significantly increased in CHF patients with highest concentration in most advanced disease. Individuals with pulmonary congestion or peripheral oedema had higher levels of BMP6 than isovolemic patients. BMP6 was not a predictor of all-cause mortality or CHF hospitalisation. BMP6 may be involved in pathophysiology of systolic CHF. BMP6 plasma level is related to the disease severity and signs of exacerbation.

Keywords: aldosterone; bone morphogenetic protein 6; diagnosis; heart failure; pathophysiology; prognosis.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Biomarkers / blood
  • Bone Morphogenetic Protein 6 / blood*
  • Chronic Disease
  • Female
  • Follow-Up Studies
  • Heart Failure / blood*
  • Heart Failure / diagnosis
  • Heart Failure / physiopathology*
  • Hospitalization / trends
  • Humans
  • Male
  • Middle Aged


  • BMP6 protein, human
  • Biomarkers
  • Bone Morphogenetic Protein 6